Oligometastatic NSCLC: definition and treatment opportunities (Ongoing)

Posted On 2020-04-22 04:09:00



This focused issue on “Oligometastatic NSCLC: definition and treatment opportunities” is edited by Drs. Maurizio V. Infante and Thierry Berghmans.

Maurizio V. Infante, MD
Head of Thoracic Surgery Department, University and Hospital Trust, Verona, Italy

2000-2016 Consultant Thoracic Surgeon, Head of the Clinical Research Unit, Thoracic Surgery Department—Humanitas Research Hospital, Milan, Italy;
2003 fellow of the Thoracic Surgery Dept., University Hospital Leuven, Belgium;
Formerly attending surgeon of the Thoracic Surgery Dept. of the National Cancer Institute of Milan, and before that a clinical research fellow in the same institution.

Teaching Experiences: In 2013, Dr. Infante was adjunct professor of the International Medical School, the first English-Language medical school in Italy, in the Humanitas Hospital; since 2017, Adjunct Professor of the University of Verona Medical School—Cardiothoracic Department.

Current Research Interests: Lung Cancer, malignant pleural mesothelioma, inflammation, immunity and lung cancer, minimally invasive surgery, lung cancer screening, lung nodule management, segmentectomy, thymoma and myasthenia gravis, and oligometastatic NSCLC. Chest wall surgery for benign and malignant conditions.

Formerly Scientific Advisor of the Italian VATS-group, promoting major lung resection by VATS for lung cancer in Italy (www.vatsgroup.it). Member of The IASLC staging and Prognostic Factors Committee as of 2018 Member of the Italian Association of Medical Oncology Lung Cancer Screening advisory board. As of January 2019, Dr. Infante has authored or co-authored 56 peer-reviewed publications on international scientific journals (1683 citations on Scopus). He was the Principal Investigator or the DANTE trial, a randomized study of LDCT screening for lung cancer.

Scientific reviewer for: Lung Cancer, Journal of Thoracic Oncology, International Journal of Cancer, Lancet Oncology, Acta Radiologica, European Respiratory Journal, Journal of Cardiothoracic Surgery, Cancer Letter, Tumori, JAMA, Respiration. Referee for Cancer Research UK, The Netherlands Organization for Health Research and Development, the Region of Emilia Romagna (Italy) Health Authority, and the National Agency for Italian Regional Health Services.

Thierry Berghmans, MD, PhD
Department of Intensive Care and Oncologic Emergencies & Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium

Thierry Berghmans is Doctor in Medicine since 1990 at the Université Libre de Bruxelles (ULB). He obtained his recognition in Internal Medicine in 1995 and was further recognised in Medical Oncology and obtained his PhD in medical science in 2008. Currently, he is Head of the Thoracic Oncology Clinic at the Institut Jules Bordet, Brussels, Belgium. He is Professor of Evidence—based Medicine at the ULB.

He is author or co-author of more than 180 original articles in peer-reviewed journals and 15 books’ chapters. He is secretary—treasurer of the European Lung Cancer Working Party and treasurer of the EORTC Lung Cancer Group. He is coordinator of cooperative academic trials as well as systematic reviews, meta-analyses and guidelines on different subjects (therapeutics, quality indicators…) in thoracic oncology, and worked as expert at consensus conferences on mesothelioma. He is reviewer of scientific journals and is Editor-in-Chief of a French language journal as well as associate editor of two “lung” journals. He is member of various international scientific societies.

Focused issue outline:

  1. Editorial 
  2. Defining OM-NSCLC-Consensus vs Biology
  3. Epidemiology of OM-NSCLC
  4. Genetics of OM-NSCLC
  5. Tumor microenvironment in OM and Oligopro-NSCLC
  6. Diagnostic and Prognostic Biomarkers in OM-NSCLC
  7. Clinical Prognostic factors in Oligometastatic NSCLC: a systematic review and meta-analysis
  8. Imaging of OM-NSCLC
  9. Alternative methods for Local ablation—interventional pulmonology
  10. The role of the surgeon in the management of OM-NSCLC
  11. Radiation Oncology for OM-NSCLC
  12. Should LAT precede or follow Systemic therapy in OM-NSCLC
  13. Immunotherapy trials in OM-NSCLC
  14. Local ablative therapy in oncogenic driven oligometastatic non-small lung cancer: present and ongoing strategies
  15. Current and future research efforts in OM-NSCLC
  16. LAT in oligopersistent and oligopro disease. What is the evidence?
  17. Editorial: Local Ablative therapy in OM-NSCLC. Is it ready for prime time?


Disclosure:
The focused issue “Oligometastatic NSCLC: definition and treatment opportunities” was commissioned by the Editorial office, Translational Lung Cancer Research without any sponsorship or funding. Maurizio V. Infante and Thierry Berghmans served as the unpaid Guest Editors for the focused issue.